Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.
We measured neutralizing antibodies (NABs) and the in vivo biologic response to interferon-beta on neopterin and beta(2)-microglobulin blood levels. All NAB-negative patients had an in vivo biologic response (full or partial), whereas all high-level positive patients had no response. High-level NAB patients had more MRI activity than NAB-negative patients (p = 0.031). Patients with a full response had less MRI activity than patients without biologic response (p = 0.032).
Sorensen
P Soelberg
PS
Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. pss@rh.dk
Tscherning
T
T
Mathiesen
H K
HK
Langkilde
A R
AR
Ross
C
C
Ravnborg
M
M
Bendtzen
K
K
D000328:Adult; D000906:Antibodies / Q000097:blood*; D001921:Brain / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D018450:Disease Progression; D004351:Drug Resistance / Q000276:immunology*; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000037:antagonists & inhibitors* / Q000276:immunology*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D019798:Neopterin / Q000097:blood / Q000276:immunology; D016896:Treatment Outcome
D000906:Antibodies; D019798:Neopterin; D016899:Interferon-beta